Conversion trial from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) in stable transplanted patients suffering from GI adverse events while on mycophenolate mofetil therapy
Phase of Trial: Phase IV
Latest Information Update: 12 Jun 2013
At a glance
- Drugs Mycophenolate sodium (Primary)
- Indications Liver transplant rejection; Renal transplant rejection
- Focus Adverse reactions
- Sponsors Novartis
- 01 Feb 2011 Actual end date (Aug 2006) added as reported by ClinicalTrials.gov.
- 01 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jun 2008 Basic check conducted, trial location ammended from NCT (03-06-2008).